FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169483924> ?p ?o ?g. }

• W3169483924 endingPage "114" @default.
• W3169483924 startingPage "107" @default.
• W3169483924 abstract "Objectives The aim of this study was to investigate the risk of TB in advanced non-small cell lung cancer (NSCLC) patients treated with Immune checkpoint inhibitors (ICI) after a platinum-based chemotherapy. Materials and methods A nationwide population-based retrospective cohort study using National health insurance dataset was designed. Patients who were diagnosed as lung cancer between September 1st, 2017 and August 31st, 2018 in South Korea were selected. Among them, those with NSCLC who initiated a platinum-based chemotherapy within 3 months were finally included and followed up until December 31st, 2018. Patients who received nivolumab, pembrolizumab, and atezolizumab within study period were classified as the ICI group. Cox proportional hazard model with time-varying covariates was used to determine effects of the duration of conventional chemotherapy, ICI, and consecutive use of systemic steroid on TB. Results A total of 6335 patients were enrolled with 3568.7 years of total follow-up period. Among them, 899 patients underwent ICI treatment. Within the follow-up period, 15 TB cases were identified in the ICI group (incidence: 2582.5 per 100,000 person-years) and 63 TB cases were found in the conventional chemotherapy group (incidence: 2108.5 per 100,000 person-years). In a multivariable Cox proportional hazard model, treatment with ICI was not a significant risk factor for TB development (hazard ratio (HR): 1.21, 95 % confidence interval (CI): 0.45−3.26,p = 0.700). Instead, prolonged use of steroid was associated with an increased TB risk (HR: 1.91, 95 %CI: 0.89−4.08, p = 0.095), although its statistical significance was dependent on the operational definition of the effect duration. Previous TB history and older age were independent risk factors for TB disease. Conclusion In this real-world study, additional treatment with ICI did not increase the risk of TB in advanced NSCLC patients who underwent a cytotoxic chemotherapy. However, TB incidence in these patients was high regardless of ICI treatment. Classifications Systemic Treatments." @default.
• W3169483924 created "2021-06-22" @default.
• W3169483924 creator A5006787063 @default.
• W3169483924 creator A5057467146 @default.
• W3169483924 creator A5083127780 @default.
• W3169483924 date "2021-08-01" @default.
• W3169483924 modified "2023-09-24" @default.
• W3169483924 title "Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors – A nationwide population-based cohort study" @default.
• W3169483924 cites W1967544081 @default.
• W3169483924 cites W1969627126 @default.
• W3169483924 cites W2049341689 @default.
• W3169483924 cites W2099717852 @default.
• W3169483924 cites W2133075384 @default.
• W3169483924 cites W2150138161 @default.
• W3169483924 cites W2164309428 @default.
• W3169483924 cites W2300884763 @default.
• W3169483924 cites W2303243520 @default.
• W3169483924 cites W2340000420 @default.
• W3169483924 cites W2373446899 @default.
• W3169483924 cites W2471356253 @default.
• W3169483924 cites W2513360745 @default.
• W3169483924 cites W2521577496 @default.
• W3169483924 cites W2560308018 @default.
• W3169483924 cites W2583586879 @default.
• W3169483924 cites W2604742992 @default.
• W3169483924 cites W2736166064 @default.
• W3169483924 cites W2738491841 @default.
• W3169483924 cites W2739331730 @default.
• W3169483924 cites W2748204910 @default.
• W3169483924 cites W2765736441 @default.
• W3169483924 cites W2780393431 @default.
• W3169483924 cites W2793633828 @default.
• W3169483924 cites W2887662393 @default.
• W3169483924 cites W2888542497 @default.
• W3169483924 cites W2896451142 @default.
• W3169483924 cites W2903883219 @default.
• W3169483924 cites W2948171622 @default.
• W3169483924 cites W2950875755 @default.
• W3169483924 cites W2971943438 @default.
• W3169483924 cites W2980132183 @default.
• W3169483924 cites W2995529115 @default.
• W3169483924 cites W2996299580 @default.
• W3169483924 cites W2998448888 @default.
• W3169483924 cites W2999475675 @default.
• W3169483924 cites W3016021502 @default.
• W3169483924 cites W3090018062 @default.
• W3169483924 cites W3107785373 @default.
• W3169483924 cites W4255758041 @default.
• W3169483924 doi "https://doi.org/10.1016/j.lungcan.2021.05.034" @default.
• W3169483924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34146757" @default.
• W3169483924 hasPublicationYear "2021" @default.
• W3169483924 type Work @default.
• W3169483924 sameAs 3169483924 @default.
• W3169483924 citedByCount "4" @default.
• W3169483924 countsByYear W31694839242022 @default.
• W3169483924 countsByYear W31694839242023 @default.
• W3169483924 crossrefType "journal-article" @default.
• W3169483924 hasAuthorship W3169483924A5006787063 @default.
• W3169483924 hasAuthorship W3169483924A5057467146 @default.
• W3169483924 hasAuthorship W3169483924A5083127780 @default.
• W3169483924 hasConcept C120665830 @default.
• W3169483924 hasConcept C121332964 @default.
• W3169483924 hasConcept C121608353 @default.
• W3169483924 hasConcept C126322002 @default.
• W3169483924 hasConcept C141071460 @default.
• W3169483924 hasConcept C143998085 @default.
• W3169483924 hasConcept C167135981 @default.
• W3169483924 hasConcept C207103383 @default.
• W3169483924 hasConcept C2775949291 @default.
• W3169483924 hasConcept C2776256026 @default.
• W3169483924 hasConcept C2777701055 @default.
• W3169483924 hasConcept C2780030458 @default.
• W3169483924 hasConcept C2780057760 @default.
• W3169483924 hasConcept C2908647359 @default.
• W3169483924 hasConcept C44249647 @default.
• W3169483924 hasConcept C50382708 @default.
• W3169483924 hasConcept C61511704 @default.
• W3169483924 hasConcept C71924100 @default.
• W3169483924 hasConcept C72563966 @default.
• W3169483924 hasConcept C99454951 @default.
• W3169483924 hasConceptScore W3169483924C120665830 @default.
• W3169483924 hasConceptScore W3169483924C121332964 @default.
• W3169483924 hasConceptScore W3169483924C121608353 @default.
• W3169483924 hasConceptScore W3169483924C126322002 @default.
• W3169483924 hasConceptScore W3169483924C141071460 @default.
• W3169483924 hasConceptScore W3169483924C143998085 @default.
• W3169483924 hasConceptScore W3169483924C167135981 @default.
• W3169483924 hasConceptScore W3169483924C207103383 @default.
• W3169483924 hasConceptScore W3169483924C2775949291 @default.
• W3169483924 hasConceptScore W3169483924C2776256026 @default.
• W3169483924 hasConceptScore W3169483924C2777701055 @default.
• W3169483924 hasConceptScore W3169483924C2780030458 @default.
• W3169483924 hasConceptScore W3169483924C2780057760 @default.
• W3169483924 hasConceptScore W3169483924C2908647359 @default.
• W3169483924 hasConceptScore W3169483924C44249647 @default.
• W3169483924 hasConceptScore W3169483924C50382708 @default.
• W3169483924 hasConceptScore W3169483924C61511704 @default.
• W3169483924 hasConceptScore W3169483924C71924100 @default.

• next